BRAF and melanoma: This acquired dependency can be exploited, as demonstrated by the hypersensitivity of BRAF-V600E melanoma cells to OXPHOS inhibitors such as 2,4-dinitrophenol, oligomycin A [83], and the ROS inducer elesclomol [82].